Study S001885

Impact of Semaglutide (Long Acting GLP1 Agonist) on Peripheral Blood Derived CD34+ Endothelial Cells (EPCs) and Subcutaneous Fat Derived Mesenchymal Stromal Cells ( MSCs) in Type 2 Diabetes Subjects

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT04126603
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 10
Start: 2019-08-01
Primary completion: 2023-10-25
Lead sponsor: Sabyasachi Sen
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Placebos
Results posted: TRUE

Registered primary outcomes

CD34+ Endothelial Progenitor Cell Number (EPC) Per Mononuclear Cells (MNC) Ratio [First Visit at Baseline and Last Visit at 24 weeks]
CD34+ Endothelial Progenitor Cell Migration (EPC) Against Serum SDF1a Gradient [First Visit at Baseline and Last Visit at 24 weeks]
Gene Expression of CD34+ Endothelial Progenitor Cell Number [First Visit at Baseline and Last Visit at 24 weeks]
CD34+ Endothelial Cell Colony Formation Unit (CFU) [First Visit at Baseline and Last Visit at 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.